$286 Million is the total value of TRV GP III, LLC's 4 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VYGR | New | VOYAGER THERAPEUTICS, INC. | $155,894,000 | – | 9,391,176 | +100.0% | 54.58% | – |
| MYOK | New | MYOKARDIA, INC. | $63,007,000 | – | 1,496,598 | +100.0% | 22.06% | – |
| JNCE | New | JOUNCE THERAPEUTICS, INC. | $38,872,000 | – | 3,048,780 | +100.0% | 13.61% | – |
| EDIT | New | EDITAS MEDICINE, INC | $27,847,000 | – | 906,176 | +100.0% | 9.75% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Mark Levin #1
- Kevin P. Starr #2
- Robert I. Tepper #3
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VOYAGER THERAPEUTICS, INC. | 22 | Q1 2023 | 74.0% |
| JOUNCE THERAPEUTICS, INC. | 20 | Q3 2022 | 24.5% |
| PLIANT THERAPEUTICS, INC. | 14 | Q3 2023 | 100.0% |
| FULCRUM THERAPEUTICS, INC. | 14 | Q4 2022 | 43.8% |
| REVOLUTION MEDICINES, INC. | 12 | Q4 2022 | 53.8% |
| DECIBEL THERAPEUTICS, INC. | 10 | Q2 2023 | 66.3% |
| NEON THERAPEUTICS, INC. | 8 | Q1 2020 | 41.1% |
| NURIX THERAPEUTICS, INC. | 8 | Q2 2022 | 17.7% |
| RELAY THERAPEUTICS, INC. | 2 | Q4 2020 | 37.7% |
| MYOKARDIA, INC. | 2 | Q1 2018 | 22.1% |
View TRV GP III, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-14 |
| 4 | 2023-02-06 |
| 4 | 2023-02-01 |
| 4 | 2023-01-31 |
| 4 | 2023-01-26 |
| 4 | 2023-01-24 |
View TRV GP III, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.